Ranbaxy posts Rs.1,045 crore net loss in 2008
March 30th, 2009 - 3:41 pm ICT by IANSMumbai, March 30 (IANS) Leading drug maker Ranbaxy Laboratories Monday reported a net loss of Rs.1,044.8 crore ($204 million) for 2008 as against a net profit of Rs.617.7 crore in the previous year.
However, the company’s total income went up 9.85 percent to Rs.4,681.7 crore in 2008 from Rs.4,261.9 crore in 2007.
The group posted a consolidated net loss of Rs.951.2 crore during the period, compared to a net profit of Rs.774.5 crore in the previous calendar year.
The total consolidated income increased 11.2 percent to Rs.7,691 crore from Rs.6,917.2 crore, the company added.
Meanwhile, the drug major, which has been in trouble with the US Food and Drug Administration over alleged falsification of test results in approved and pending drug applications, Monday said the US drug regulator had given it the nod to sell topirimate tablets - a medication used for the treatment of seizures.
The drug is a generic version of epilepsy drug Topamax, owned by a unit of Johnson and Johnson.
- Infosys net profit up 9.7 percent in fiscal 2010-11 - Apr 15, 2011
- Infosys net up 33 percent in third quarter - Jan 12, 2012
- Cairn India consolidated net profit declines 11 percent - Apr 20, 2012
- Jet Airways posts net profit of Rs.9.69 crore - May 19, 2011
- Tech Mahindra Q2 consolidated net profit rises 59.6 percent - Nov 15, 2011
- Malvinder Singh steps down as Ranbaxy chief executive - May 24, 2009
- DLF's Q1 net profit down 55 percent - Aug 02, 2011
- Reliance Infra quarterly operating income rises 66 percent - Feb 14, 2012
- ICICI's third quarter net profit up 20.25 percent - Jan 31, 2012
- TCS net up 30 percent in third quarter - Jan 17, 2011
- Srei Infra's Q3 net slips by 51.8 percent - Feb 03, 2012
- Ranbaxy's June quarter net profit falls by 25 pc - Aug 05, 2011
- Reliance Capital Q1 profit dips 49 percent - Aug 09, 2010
- MindTree net plunges 53 percent in fiscal 2010-11 - Apr 21, 2011
- Infosys net up 27 percent in fourth quarter - Apr 13, 2012
Tags: calendar year, consolidated income, drug applications, epilepsy, falsification, food and drug, food and drug administration, generic version, johnson and johnson, medication, net profit, nod, previous year, rs 6, seizures, test results, topamax, us food and drug administration